What is Thymosin Alpha-1?

Thymosin Alpha-1 (Ta1) is a 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein in the 1970s. It is derived from the N-terminal region of prothymosin alpha, a 111-amino acid precursor protein. Ta1 is now chemically synthesised via solid-phase peptide synthesis and is available as thymalfasin (INN) in research and clinical settings internationally.

Unlike many immune-targeting research compounds, Thymosin Alpha-1 has an unusually well-characterised mechanism of action focused on T-lymphocyte maturation and dendritic cell activation, with a safety profile established across multiple clinical programmes.

For research use only. Not for human consumption. All findings cited derive from in vitro or animal pre-clinical models unless otherwise specified.

Mechanism of Action: T-Cell Maturation

Thymosin Alpha-1 acts primarily on immature T-cell precursors and mature T-cell subsets. Key mechanistic findings from in vitro and ex vivo studies include:

  • Thymocyte differentiation: Ta1 promotes the differentiation of CD4-CD8- double-negative thymocytes into functional CD4+ and CD8+ single-positive T cells, a process critical for establishing adaptive immune repertoire diversity
  • Th1 polarisation: In peripheral blood mononuclear cell (PBMC) cultures, Ta1 shifts the CD4+ T-helper balance toward Th1 responses, increasing IFN-gamma and IL-2 production while reducing IL-4 and IL-13 secretion
  • T-regulatory cell modulation: At physiological concentrations, Ta1 has been shown to support FoxP3+ T-regulatory cell function without suppressing effector T-cell responses, a balance relevant to autoimmune research models

Dendritic Cell Activation

In monocyte-derived dendritic cell (moDC) cultures, Ta1 enhances TLR9-mediated activation pathways, upregulating co-stimulatory molecules (CD80, CD86), increasing MHC-II surface expression, and promoting IL-12p70 secretion. This effect is synergistic with CpG oligonucleotides in DC maturation assays, suggesting Ta1 may amplify pattern recognition receptor-driven immune activation in research contexts.

NK Cell and Macrophage Effects

Thymosin Alpha-1 increases natural killer (NK) cell cytotoxicity in ex vivo assays, with significant dose-dependent enhancement of NK lysis of K562 target cells at concentrations of 10-100 ng/mL. In macrophage cultures, Ta1 promotes phagocytic activity, increases ROS burst in response to PMA, and upregulates MHC-II and FcgammaR expression.

Antiviral Research Models

Ta1 has been studied extensively in antiviral research contexts. In hepatitis B and C antigen-presenting cell models, Ta1 enhanced specific T-cell responses to viral antigens and increased IFN-alpha production in plasmacytoid dendritic cells. In influenza-exposed murine models, Ta1 administration reduced viral titres in lung tissue and improved survival outcomes compared to controls, associated with augmented CD8+ cytotoxic T-lymphocyte (CTL) responses.

Research Applications and Formats at Stackpure

Stackpure provides Thymosin Alpha-1 in the following research formats:

All Stackpure Thymosin Alpha-1 is verified at +99% HPLC purity with mass spectrometry confirmation and an independent COA per batch.

Key References

  • Goldstein AL et al. (1981). Thymosin: isolation, structure, immunological properties and role in the maturation of T cells. Recent Progress in Hormone Research, 37:369-415.
  • Romani L et al. (2012). Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood, 108(7):2265-2274.
  • Dominari A et al. (2020). Thymosin alpha 1: a comprehensive review of the literature. World Journal of Virology, 9(5):67-78.

All content is for in vitro research reference only. Not for human or veterinary use.